Elan Drug Technologies Announces First Japanese Approval Of Product Using Its NanoCrystal(R) Technology

Posted by Jeff Daas on Dec 14th, 2009 | no comments

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting. EMEND®, which was developed by a subsidiary of Merck & Co Inc., Whitehouse Station, N.J., USA and licensed to Ono Pharmaceuticals Co., Ltd…
Read Full Article